BR112018070919A2 - anticorpos anti-tim-3 e composições - Google Patents

anticorpos anti-tim-3 e composições

Info

Publication number
BR112018070919A2
BR112018070919A2 BR112018070919A BR112018070919A BR112018070919A2 BR 112018070919 A2 BR112018070919 A2 BR 112018070919A2 BR 112018070919 A BR112018070919 A BR 112018070919A BR 112018070919 A BR112018070919 A BR 112018070919A BR 112018070919 A2 BR112018070919 A2 BR 112018070919A2
Authority
BR
Brazil
Prior art keywords
tim
antibodies
compositions
patient
relates
Prior art date
Application number
BR112018070919A
Other languages
English (en)
Inventor
Roland Galler Gunther
David Horak Ivan
Koefoed Klaus
Kragh Michael
Monrad Grandal Michael
Wandahl Pedersen Mikkel
Gad Monika
Bouquin Thomas
Gjetting Torben
Lindsted Trine
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Publication of BR112018070919A2 publication Critical patent/BR112018070919A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

a presente invenção se refere a anticorpos anti-tim-3 e composições de anticorpos e a sua utilização no reforço de imunidade em um paciente, por exemplo, para tratar câncer.
BR112018070919A 2016-04-12 2017-04-11 anticorpos anti-tim-3 e composições BR112018070919A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662321476P 2016-04-12 2016-04-12
PCT/EP2017/058696 WO2017178493A1 (en) 2016-04-12 2017-04-11 Anti-tim-3 antibodies and compositions

Publications (1)

Publication Number Publication Date
BR112018070919A2 true BR112018070919A2 (pt) 2019-01-29

Family

ID=58547516

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018070919A BR112018070919A2 (pt) 2016-04-12 2017-04-11 anticorpos anti-tim-3 e composições

Country Status (34)

Country Link
US (2) US11390674B2 (pt)
EP (2) EP3443009B1 (pt)
JP (2) JP7123804B2 (pt)
KR (1) KR102473028B1 (pt)
CN (2) CN116693685A (pt)
AU (1) AU2017251250B2 (pt)
BR (1) BR112018070919A2 (pt)
CA (1) CA3020647A1 (pt)
CL (1) CL2018002878A1 (pt)
CO (1) CO2018010458A2 (pt)
CY (1) CY1125440T1 (pt)
DK (1) DK3443009T3 (pt)
EA (1) EA039020B1 (pt)
ES (1) ES2900381T3 (pt)
HR (1) HRP20211820T1 (pt)
HU (1) HUE056677T2 (pt)
IL (1) IL262176B2 (pt)
LT (1) LT3443009T (pt)
MA (1) MA44659B1 (pt)
MD (1) MD3443009T2 (pt)
MX (1) MX2018012076A (pt)
PE (1) PE20181805A1 (pt)
PH (1) PH12018502112A1 (pt)
PL (1) PL3443009T3 (pt)
PT (1) PT3443009T (pt)
RS (1) RS62736B1 (pt)
SA (1) SA518400222B1 (pt)
SG (2) SG11201808724SA (pt)
SI (1) SI3443009T1 (pt)
TN (1) TN2018000333A1 (pt)
TW (1) TWI752950B (pt)
UA (1) UA126854C2 (pt)
WO (1) WO2017178493A1 (pt)
ZA (1) ZA201806429B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107743495B (zh) 2015-03-23 2021-05-14 拜耳制药股份公司 抗ceacam6抗体及其用途
CN117683135A (zh) 2016-07-14 2024-03-12 百时美施贵宝公司 针对tim3的抗体及其用途
MA49042A (fr) 2017-04-05 2020-02-12 Symphogen As Polythérapies ciblant pd-1, tim-3 et lag-3
KR20200044899A (ko) 2017-08-28 2020-04-29 브리스톨-마이어스 스큅 컴퍼니 암의 치료 및 진단을 위한 tim-3 길항제
KR20200108870A (ko) * 2018-01-12 2020-09-21 브리스톨-마이어스 스큅 컴퍼니 Tim3에 대한 항체 및 그의 용도
WO2019179420A1 (en) * 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel anti-tim-3 antibodies
CN111886256A (zh) 2018-03-23 2020-11-03 百时美施贵宝公司 抗mica和/或micb抗体及其用途
US11807683B2 (en) 2018-04-12 2023-11-07 Nanjing Leads Biolabs Co., Ltd. Antibody binding TIM-3 and use thereof
CA3098096A1 (en) 2018-04-24 2019-10-31 Ampsource Biopharma Shanghai Inc. Antibody against tim-3 and application thereof
CA3108879A1 (en) * 2018-08-21 2020-02-27 Albert Einstein College Of Medicine Monoclonal antibodies against human tim-3
CN111253485A (zh) * 2018-11-30 2020-06-09 上海开拓者生物医药有限公司 抗人tim-3单克隆抗体及其应用
US20220089721A1 (en) 2018-12-19 2022-03-24 Bayer Aktiengesellschaft Pharmaceutical combination of anti ceacam6 and tim3 antibodies
JP2022534967A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 多腫瘍遺伝子シグネチャーおよびその使用
KR20220016157A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 세포 국재화 시그너쳐 및 조합 요법
CN114127315A (zh) 2019-05-30 2022-03-01 百时美施贵宝公司 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
CN113214396B (zh) * 2020-07-31 2022-04-19 北京市神经外科研究所 抗tim3的单链抗体及其在制备治疗肿瘤的药物中的用途
AU2021334361A1 (en) 2020-08-31 2023-05-11 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
US20220233689A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Methods of treating tumors
US20220233693A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Antibody Compositions and Methods of Use Thereof
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
CA3222040A1 (en) * 2021-06-01 2022-12-08 Les Laboratoires Servier Anti-nkg2a antibodies and compositions
CA3230117A1 (en) 2021-09-02 2023-03-09 Mark Trautwein Anti-cecam6 antibodies with reduced side-effects
IL310958A (en) 2021-09-03 2024-04-01 Oncoone Res & Development Gmbh Enhanced Fc-silenced anti-oxMIF antibodies with reduced aggregation potential and reduced hydrophobicity
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
JP2532858B2 (ja) 1985-04-01 1996-09-11 セルテツク リミテツド 形質転換したミエロ―マ細胞系
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
AU770555B2 (en) 1998-08-17 2004-02-26 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
EP2252319A2 (en) 2008-01-29 2010-11-24 The Brigham and Women's Hospital, Inc. Methods for modulating a population of myeloid-derived suppressor cells and uses thereof
JP5569946B2 (ja) 2009-01-26 2014-08-13 国立大学法人 岡山大学 免疫抑制剤および自己免疫疾患の予防および治療剤
EP2417984B1 (en) 2009-04-10 2016-03-30 Kyowa Hakko Kirin Co., Ltd. Method for treatment of blood tumor using anti-tim-3 antibody
PL2581113T3 (pl) * 2010-06-11 2018-11-30 Kyowa Hakko Kirin Co., Ltd. Przeciwciało anty-tim-3
JP2013532153A (ja) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
WO2013006490A2 (en) * 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
CN103936853B (zh) 2014-01-26 2016-08-17 中国人民解放军军事医学科学院基础医学研究所 一种检测tim-3试剂盒及其使用方法
JOP20200096A1 (ar) * 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
NZ747418A (en) 2014-03-12 2023-05-26 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
AU2015259516B2 (en) 2014-05-13 2020-05-28 Bavarian Nordic A/S Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against TIM-3
WO2016111947A2 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
MX2017011406A (es) * 2015-03-06 2018-06-19 Sorrento Therapeutics Inc Terapeuticos de anticuerpo que se unen a tim3.
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP3337826A1 (en) 2015-08-20 2018-06-27 Sutro Biopharma, Inc. Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
MY192202A (en) 2015-10-02 2022-08-06 Hoffmann La Roche Bispecific antibodies specific for pd1 and tim3
CN117683135A (zh) 2016-07-14 2024-03-12 百时美施贵宝公司 针对tim3的抗体及其用途
JOP20190013A1 (ar) 2016-08-25 2019-01-31 Lilly Co Eli أجسام مضادة لـ (تي آي ام -3)
JOP20190133A1 (ar) 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
MA49042A (fr) 2017-04-05 2020-02-12 Symphogen As Polythérapies ciblant pd-1, tim-3 et lag-3
JOP20190222A1 (ar) 2017-04-11 2019-09-24 Zymeworks Inc الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3

Also Published As

Publication number Publication date
SI3443009T1 (sl) 2022-04-29
PE20181805A1 (es) 2018-11-19
ES2900381T3 (es) 2022-03-16
AU2017251250B2 (en) 2024-03-21
DK3443009T3 (da) 2021-12-13
PH12018502112A1 (en) 2019-09-23
PL3443009T3 (pl) 2022-01-31
MA44659A (fr) 2021-04-14
JP2019519199A (ja) 2019-07-11
LT3443009T (lt) 2021-12-27
TWI752950B (zh) 2022-01-21
EP3978531A1 (en) 2022-04-06
AU2017251250A1 (en) 2018-10-18
MA44659B1 (fr) 2021-12-31
ZA201806429B (en) 2023-02-22
PT3443009T (pt) 2021-12-10
HUE056677T2 (hu) 2022-02-28
WO2017178493A1 (en) 2017-10-19
JP2022172142A (ja) 2022-11-15
KR20180133482A (ko) 2018-12-14
HRP20211820T1 (hr) 2022-03-04
IL262176B2 (en) 2023-03-01
EA201892294A1 (ru) 2019-04-30
EA039020B1 (ru) 2021-11-23
RS62736B1 (sr) 2022-01-31
KR102473028B1 (ko) 2022-11-30
SA518400222B1 (ar) 2022-03-14
CN109451741A (zh) 2019-03-08
CO2018010458A2 (es) 2018-10-10
CY1125440T1 (el) 2023-03-24
IL262176A (en) 2018-11-29
CL2018002878A1 (es) 2019-04-26
US11390674B2 (en) 2022-07-19
SG11201808724SA (en) 2018-11-29
EP3443009A1 (en) 2019-02-20
MX2018012076A (es) 2019-02-20
SG10201912937SA (en) 2020-02-27
US20230105714A1 (en) 2023-04-06
EP3443009B1 (en) 2021-09-08
CN116693685A (zh) 2023-09-05
TW201736397A (zh) 2017-10-16
TN2018000333A1 (en) 2020-01-16
MD3443009T2 (ro) 2022-02-28
IL262176B (en) 2022-11-01
CN109451741B (zh) 2023-07-28
US20190276531A1 (en) 2019-09-12
UA126854C2 (uk) 2023-02-15
CA3020647A1 (en) 2017-10-19
JP7123804B2 (ja) 2022-08-23

Similar Documents

Publication Publication Date Title
BR112018070919A2 (pt) anticorpos anti-tim-3 e composições
CY1122804T1 (el) Μονοκλωνικα αντισωματα εναντι ανθρωπινου αντιγονου ωριμανσης β κυτταρων (βcμα)
CY1121893T1 (el) Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων
BR112017001588A2 (pt) conjugados de anticorpo/fármaco anti-cdh6
BR112018067525A2 (pt) anticorpos tendo especificidade para o btla e seus usos
MD3273992T2 (ro) Anticorpi pentru ICOS
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
EA201891339A1 (ru) Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб
BR112018073574A2 (pt) conjugados de anticorpo-fármaco anti-cmet e métodos para a sua utilização
TN2015000396A1 (en) Antibody drug conjugates
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
BR112016025291A2 (pt) conjugados de anticorpo anti-ptk7-fármaco
PH12018501043A1 (en) Site specific her2 antibody drug conjugates
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
EA201792058A1 (ru) Виротерапия комбинацией антител
BR112018002382A8 (pt) Novos anticorpos anti-gvpi humano e usos dos mesmos
BR112018013268A2 (pt) composições e métodos para detectar e tratar câncer gástrico
BR112016015078A2 (pt) método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica
BR112018013271A2 (pt) composições e métodos para detectar e tratar câncer de ovário
EA201892068A1 (ru) Конъюгаты napi2b-нацеленное антитело-лекарственное средство и способы их применения

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25A Requested transfer of rights approved

Owner name: LES LABORATOIRES SERVIER (FR)